JNJ-18038683

CAS Number

• 851373-91-6

PubChem CID

• 11151899

ChemSpider

• 9327007

UNII

• 28PGH5X4OQ

JNJ-18038683

Identifiers
IUPAC name 1-benzyl-3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4H-pyrazolo[3,4-d]azepine
CAS Number	851373-91-6
PubChem CID	11151899
ChemSpider	9327007
UNII	28PGH5X4OQ
CompTox Dashboard (EPA)	DTXSID001336543
Chemical and physical data
Formula	C20H20ClN3
Molar mass	337.85 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CNCCC2=C1C(=NN2CC3=CC=CC=C3)C4=CC=C(C=C4)Cl
InChI InChI=1S/C20H20ClN3/c21-17-8-6-16(7-9-17)20-18-10-12-22-13-11-19(18)24(23-20)14-15-4-2-1-3-5-15/h1-9,22H,10-14H2 Key:UKJPMZGILXATGT-UHFFFAOYSA-N

JNJ-18038683 is a potent and selective antagonist of the 5HT₇ serotonin receptor discovered by Johnson & Johnson. It has nootropic and antidepressant effects in both animal and human studies and has progressed to Phase II trials as an adjunctive treatment for improving cognition and mood in stable bipolar disorder; it has been found to reduce REM sleep (the lightest stage of sleep, elevated in depression) in humans and block circadian rhythm phase-shift advances in mice.^[1][2]

It binds to the 5-HT6 serotonin receptor with 10x less affinity.^[3] At relevant doses, inhibition of 5-HT6 would be expected to render pro-cognitive and anti-dementia effects.^[4][5]